Daiichi Sankyo Tribenzor Receives FDA Nod
Daiichi Sankyo claimed that a fixed-dose combination treatment, Tribenzor, simplifies dosing regimens and reduces pill burden. Research also shows that the use of fixed-dose antihypertensive combination treatments may
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.